Gene Therapy for Carcinoma of the Breast: Genetic Toxins

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2001 Mar 16

PMID 11250689

Authors

G Vassaux

N R Lemoine

Affiliations

Soon will be listed here.

Abstract

Gene therapy was initially envisaged as a potential treatment for genetically inherited, monogenic disorders. The applications of gene therapy have now become wider, however, and include cardiovascular diseases, vaccination and cancers in which conventional therapies have failed. With regard to oncology, various gene therapy approaches have been developed. Among them, the use of genetic toxins to kill cancer cells selectively is emerging. Two different types of genetic toxins have been developed so far: the metabolic toxins and the dominant-negative class of toxins. This review describes these two different approaches, and discusses their potential applications in cancer gene therapy.

References

Cortes M, de Felipe P, Martin V, Hughes M, Izquierdo M . Successful use of a plant gene in the treatment of cancer in vivo. Gene Ther. 1999; 5(11):1499-507. DOI: 10.1038/sj.gt.3300751. View

Senmaru N, Shichinohe T, Takeuchi M, Miyamoto M, Sazawa A, Ogiso Y . Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y. Int J Cancer. 1998; 78(3):366-71. DOI: 10.1002/(SICI)1097-0215(19981029)78:3<366::AID-IJC18>3.0.CO;2-4. View

Vassaux G, Hurst H, Lemoine N . Insulation of a conditionally expressed transgene in an adenoviral vector. Gene Ther. 1999; 6(6):1192-7. DOI: 10.1038/sj.gt.3300910. View

Kokoris M, Sabo P, Adman E, Black M . Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther. 1999; 6(8):1415-26. DOI: 10.1038/sj.gt.3300966. View

Peng K . Strategies for targeting therapeutic gene delivery. Mol Med Today. 1999; 5(10):448-53. DOI: 10.1016/s1357-4310(99)01579-8. View

Kuriyama S, Masui K, Sakamoto T, Nakatani T, Kikukawa M, Tsujinoue H . Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res. 1998; 18(5A):3399-406. View

Pandha H, Martin L, Rigg A, Hurst H, Stamp G, Sikora K . Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol. 1999; 17(7):2180-9. DOI: 10.1200/JCO.1999.17.7.2180. View

Mar E, Chiou J, Cheng Y, Huang E . Inhibition of cellular DNA polymerase alpha and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Virol. 1985; 53(3):776-80. PMC: 254706. DOI: 10.1128/JVI.53.3.776-780.1985. View

Clanton D, Hattori S, Shih T . Mutations of the ras gene product p21 that abolish guanine nucleotide binding. Proc Natl Acad Sci U S A. 1986; 83(14):5076-80. PMC: 323893. DOI: 10.1073/pnas.83.14.5076. View

10.

Maxwell I, Maxwell F, Glode L . Regulated expression of a diphtheria toxin A-chain gene transfected into human cells: possible strategy for inducing cancer cell suicide. Cancer Res. 1986; 46(9):4660-4. View

11.

Reid R, Mar E, Huang E, Topal M . Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human alpha and human beta polymerases. A unique inhibition mechanism for 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J Biol Chem. 1988; 263(8):3898-904. View

12.

Pinedo H, Peters G . Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988; 6(10):1653-64. DOI: 10.1200/JCO.1988.6.10.1653. View

13.

Bos J . ras oncogenes in human cancer: a review. Cancer Res. 1989; 49(17):4682-9. View

14.

Lovekin C, Ellis I, Locker A, Robertson J, Bell J, Nicholson R . c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer. 1991; 63(3):439-43. PMC: 1971868. DOI: 10.1038/bjc.1991.101. View

15.

van der Wilt C, Pinedo H, Smid K, Cloos J, Noordhuis P, Peters G . Effect of folinic acid on fluorouracil activity and expression of thymidylate synthase. Semin Oncol. 1992; 19(2 Suppl 3):16-25. View

16.

Culver K, Ram Z, Wallbridge S, Ishii H, Oldfield E, Blaese R . In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992; 256(5063):1550-2. DOI: 10.1126/science.1317968. View

17.

Moolten F, Wells J, Mroz P . Multiple transduction as a means of preserving ganciclovir chemosensitivity in sarcoma cells carrying retrovirally transduced herpes thymidine kinase genes. Cancer Lett. 1992; 64(3):257-63. DOI: 10.1016/0304-3835(92)90051-v. View

18.

Knox R, Friedlos F, Boland M . The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev. 1993; 12(2):195-212. DOI: 10.1007/BF00689810. View

19.

Freeman S, Abboud C, Whartenby K, Packman C, Koeplin D, Moolten F . The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993; 53(21):5274-83. View

20.

Mullen C, Coale M, Lowe R, Blaese R . Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 1994; 54(6):1503-6. View